Gold nanoparticle aggregates (red) are observed inside triple negative breast cancer cells after an enzyme-activated assembly and internalization process.
(photo credit: Richard Huang and Ye He)
The breakthrough advance could lead to a novel, drug-free therapeutic that can slow, possibly stop, the growth of cancer cells
A multi-institutional research team has designed nanoparticles that can communicate with and slow the development of cancer cells. The work — detailed in a newly published paper in Advanced Materials — has uncovered a novel framework for the potential development of drug-free cancer therapies.
Led by scientists at the Advanced Science Research Center at the Graduate Center, CUNY (CUNY ASRC), the research team was able to design nanoparticles that are activated to self-assemble when they encounter cancer cells and send messages to instruct the cells to slow their growth. Because the nanoparticles communicate only with the cancer cells, the surrounding healthy cells aren’t impacted.
“Cancer cells take up materials from their environment, and they also secrete factors that help them degrade surrounding tissue in order to spread and metastasize,” said Richard Huang, lead author of the paper, a Ph.D. student at the Graduate Center, CUNY (GC CUNY), and a researcher with the CUNY ASRC Nanoscience Initiative and the Center for Discovery and Innovation at CUNY’s City College of New York (CCNY). “We made particles that respond to both of these characteristics by aggregating into clusters that are actively taken up by cancer cells. Once inside, they appear to be able to reduce the cancer cells’ metabolic activity and consequently reduce their growth.
One reason the progression of cancer is difficult to control is that the cells secrete an abnormally large amount of the matrix metalloproteinase-9 (MMP-9) enzyme, which breaks down the collagen that holds together healthy tissue. The research team was able to use this feature against the cancer cells. This is achieved by designing nanoparticles that when triggered by MMP-9, begin assembling to large aggregates in the cells’ vicinity. The cells engulf these aggregates, and their size causes physical distress to the cancer cells and reduces their ability to proliferate and survive.
One highlight of the study is that the researchers were able to use confocal reflection microscopy to visualize the nanoparticle aggregates inside the cancer cells in real-time. “This label-free, live imaging technique allowed us to have a closer look at when and where the aggregates were formed, and how the cancer cells respond to the particles at the sub-cellular level,” said Ye He, director of the Live Imaging and Bioenergetics Facility in the CUNY ASRC Neuroscience Initiative.
“Through this research, we wanted to determine whether it’s possible to make use of relatively simple peptide design to create nanoparticles that could produce robust self-assembly in biological media and have an impact on cancer cells,” said Rein Ulijn, director of the CUNY ASRC Nanoscience Initiative and the study’s principal investigator. “While this is early-stage research, the findings provide exciting possibilities for a drug-free therapeutic treatment that could be extremely useful for cancer patients who have developed drug resistance and for extending the lives of people with metastatic cancer.”
Further studies are needed to fully access the therapeutic potential of the team’s discovery.
Original Article: Scientists Design Nanoparticles That Communicate With Cancer Cells
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- Nanotechnology for Treatment of Stroke and Spinal Cord Injury
Magnetic nanoparticles for labeling stem cells ... regeneration and the re-establishment of damaged connections. Self-assembling nanofibers with incorporated specific functional ligands promote ...
- Nanomedicine Strategies for Hematological Malignancies: What Is Next?
While nanoparticles are usually designed for ... CLL-L1 Suitable carrier for water-insoluble drugs; biocompatible, self-assembling, biodegradable; ease of functional modification; targeting ...
- Nanoparticle Suspension and Ultrasound Deliver Insulin Without Regular Injections
A nanotechnoly developed at North Carolina State University and the University of North Carolina at Chapel Hill may end all that thanks to a self-assembling network that can release insulin ...
- Spiral self-assembly of lamellar micelles into multi-shelled hollow nanospheres with unique chiral architecture
The micelle-directed self-assembly offered a simple and powerful ... As the reaction goes on, the PDA nanoparticles gradually transform from spoon-like particle to multi-shelled nanospheres ...
- Groundbreaking Research Paves Way for Preprogrammable Self-Assembly of Nanoparticles, Endless Nanomedical Applications
Nanotechnology has been the focus of vast global research in recent years, producing advancements in materials sciences, medicine, and other relevant fields on a scale previously unimaginable.
Go deeper with Google Headlines on:
Go deeper with Bing News on:
Drug-free cancer treatment
- Merck, AstraZeneca's sNDA for breast cancer treatment granted priority review by the FDA
Merck & Co. Inc. and AstraZeneca PLC said Tuesday that their supplemental New Drug Application (sNDA) for its breast cancer treatment Lynparza has been accepted and granted priority review by the U.S.
- LYNPARZA® (olaparib) Granted Priority Review in the US for BRCA-Mutated HER2-Negative High-Risk Early Breast Cancer
AstraZeneca’s supplemental New Drug Application (sNDA) for LYNPARZA® (olaparib) has been accepted and granted Priority Review in the US for the adjuvant treatment of patients with BRCA-mutated (BRCAm) ...
- AstraZeneca cancer drug Lynparza is granted priority review in US
AstraZeneca PLC on Tuesday said the US Food & Drug Administration granted its supplemental new cancer treatment drug Lynparza a priority review. Lynparza will be reviewed for the treatment of patients ...
- AZ eyes FDA verdict on Lynparza in adjuvant breast cancer in Q1
FDA grants a priority review to AstraZeneca and Merck's PARP drug Lynparza in adjuvant breast cancer, a use which could significantly expand the eligible patient population if approved ...
- AstraZeneca's Lynparza Granted Priority Review In U.S. For High-risk Early Breast Cancer
(AZN.L, AZN) said that its supplemental New Drug Application or sNDA for Lynparza or olaparib has been granted Priority Review in the US for the adjuvant treatment of patients with BRCA-mutated or ...